carmustine has been researched along with Malignant Melanoma in 185 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 9.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 9.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "One hundred seventy-six eligible patients with advanced melanoma were randomized to receive CT (cisplatin and dacarbazine with or without carmustine every 21 days) or bioCT comprising the same CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week, both for six cycles." | 9.10 | Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. ( Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P, 2002) |
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 9.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)." | 9.09 | A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. ( Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N, 2000) |
| "Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients." | 9.09 | Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. ( Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM, 1999) |
| "This study assessed response rates to combination dacarbazine (DTIC), BCNU (carmustine), cisplatin and tamoxifen (DBPT) chemotherapy in patients with progressive metastatic melanoma previously treated with DTIC, as an evaluation of DBPT as a second-line regimen, and as an indirect comparison of DBPT with DTIC." | 9.09 | Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. ( Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC, 2000) |
| "A prospective randomized phase III clinical trial was conducted to assess whether the addition of tamoxifen (TAM) to the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progression-free survival and overall survival of patients with advanced malignant melanoma." | 9.09 | Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. ( Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM, 1999) |
| "A phase II trial was conducted to determine the efficacy and toxicity of the addition of interferon-alpha 2b (IFN-alpha) to the chemotherapy combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV melanoma." | 9.08 | A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. ( Buzaid, AC; Poo, WJ; Schultz, MZ, 1997) |
| " This Phase II trial was designed to assess the efficacy of a strategy designed to modulate the resistance to carmustine (BCNU) mediated by AGAT using streptozocin (STZ) in patients with advanced refractory melanoma." | 9.08 | Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. ( Day, R; Donnelly, S; Gerson, SL; Kirkwood, JM; Liu, L; Smith, DC; Trump, DL, 1996) |
| "Since cytotoxic chemotherapy (BCNU, DTIC and cisplatin, tamoxifen) and interferon-alpha (IFN-alpha) have each produced responses in advanced malignant melanoma, a phase II trial was conducted to evaluate the response and toxicity of simultaneous administration of both therapies." | 9.08 | Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. ( Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N, 1995) |
| "We designed and conducted a randomized, double-blind, placebo-controlled trial to compare the response rates and survival of patients with metastatic melanoma who received carmustine (BCNU), dacarbazine (DTIC), and cisplatin with tamoxifen, or the same chemotherapy with placebo." | 9.08 | Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. ( Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B, 1996) |
| "Laboratory data suggest a synergistic interaction between carmustine (BCNU) and tumour necrosis factor (TNF) in melanoma." | 9.07 | A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma. ( Gore, ME; Hanrahan, A; Jones, AL; Lorentzos, A; Millar, JL; Moore, J; O'Brien, ME; Viner, C, 1992) |
| " Megestrol acetate may ameliorate cachexia, abrogate drug resistance, and increase survival time in melanoma." | 9.07 | Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin. ( Losada, R; Meelu, MA; Nathanson, L, 1994) |
| "We have attempted to review the data regarding the activity of tamoxifen (TAM) to clarify the role of this agent in the treatment of metastatic melanoma." | 8.79 | Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? ( McClay, EF; McClay, ME, 1994) |
| "In the present study, we have investigated the influence of telomerase inhibition in chemosensitivity of melanoma cells to temozolomide (TMZ), a methylating agent with promising antitumor activity against metastatic melanoma." | 7.72 | Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. ( Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M, 2003) |
| "Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma." | 7.72 | Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. ( Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY, 2003) |
| "Dacarbazine (DTIC) is the only single-agent approved by the Food and Drug Administration for treating metastatic melanoma." | 7.70 | Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. ( Cognetti, F; Sega, FM; Serrone, L; Zeuli, M, 2000) |
| "Exposure of cultured human melanoma cells from three different cell lines to Adriamycin and carmustine at non-cytotoxic (micromolar) concentrations results in a rapid, reversible depletion of cellular glutathione; maximal depletion is achieved within 1 h, and glutathione levels recover within 2-3 h." | 7.68 | Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine. ( Guenthner, TM; Jevtorić-Todorović, V; Jevtović-Todorović, V, 1991) |
| "Sixty-two patients with biopsy-proven, measurable disseminated malignant melanoma received either the combination IFN-alpha 2A with BCNU (30 patients) or the combination cimetidine with BCNU (32 patients) in parallel noncomparative Phase II trials." | 7.68 | Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma. ( Creagan, ET; Kardinal, CG; McCormack, GW; McHale, MS; Morton, RF; Schaid, DJ; Wiesenfeld, M, 1991) |
| "A prospective, nonrandomized trial was performed of the four-drug chemotherapy protocol consisting of dacarbazine, carmustine, cisplatin, and tamoxifen citrate given to high-risk patients for recurrence of melanoma after local regional treatment." | 7.68 | Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. ( Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE, 1992) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 7.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Sodium cyanate injected IP at a dose level of 200 or 250 mg/kg caused a 90% or greater inhibition of the incorporation of [3H]thymidine into DNA of B16 melanoma transplanted SC in mice." | 7.67 | Effects of sodium cyanate in mice bearing B16 melanoma. ( Carpenter, L; Hill, GJ; Hill, HZ; Lea, MA; Luke, A; Martinson, CF; Velazquez, O, 1986) |
| "We investigated the effects of combinations of BCNU and misonidazole, and melphalan and misonidazole on growth delay in two human malignant melanoma xenograft lines grown in immune-deprived mice." | 7.66 | Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts. ( Clutterbuck, RD; McElwain, TJ; Millar, JL, 1982) |
| "One hundred twenty-one patients with disseminated malignant melanoma were treated with BCNU, vincristine, DTIC, and chlorpromazine (BVD)." | 7.65 | Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. ( Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK, 1977) |
| "Metastatic melanoma has a grim prognosis." | 6.68 | Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. ( Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T, 1995) |
| "Melanoma is rare in Singapore with an age-standardised rate (ASR) of 0." | 6.68 | Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. ( Ang, PT; Tan, EH, 1996) |
| "Metastatic melanoma is difficult to treat because of low response rates to most chemotherapy regimens and short remission durations." | 5.29 | The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. ( Crowell, EB; Higa, GM, 1993) |
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 5.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 5.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "One hundred seventy-six eligible patients with advanced melanoma were randomized to receive CT (cisplatin and dacarbazine with or without carmustine every 21 days) or bioCT comprising the same CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week, both for six cycles." | 5.10 | Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. ( Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P, 2002) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 5.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "The combination of carmustine, cisplatin, dacarbazine, interferon, and low-dose tamoxifen is widely used in treating metastatic melanoma and was originally reported to achieve a 20% complete response rate." | 5.09 | Sustained complete remission after chemobiohormonal therapy for metastatic melanoma. ( Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M, 1999) |
| "A prospective randomized phase III clinical trial was conducted to assess whether the addition of tamoxifen (TAM) to the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progression-free survival and overall survival of patients with advanced malignant melanoma." | 5.09 | Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. ( Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM, 1999) |
| "This study assessed response rates to combination dacarbazine (DTIC), BCNU (carmustine), cisplatin and tamoxifen (DBPT) chemotherapy in patients with progressive metastatic melanoma previously treated with DTIC, as an evaluation of DBPT as a second-line regimen, and as an indirect comparison of DBPT with DTIC." | 5.09 | Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. ( Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC, 2000) |
| "The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)." | 5.09 | A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. ( Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N, 2000) |
| "Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients." | 5.09 | Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. ( Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM, 1999) |
| "Since cytotoxic chemotherapy (BCNU, DTIC and cisplatin, tamoxifen) and interferon-alpha (IFN-alpha) have each produced responses in advanced malignant melanoma, a phase II trial was conducted to evaluate the response and toxicity of simultaneous administration of both therapies." | 5.08 | Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. ( Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N, 1995) |
| "We designed and conducted a randomized, double-blind, placebo-controlled trial to compare the response rates and survival of patients with metastatic melanoma who received carmustine (BCNU), dacarbazine (DTIC), and cisplatin with tamoxifen, or the same chemotherapy with placebo." | 5.08 | Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. ( Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B, 1996) |
| "Eligible patients with measurable metastatic melanoma received carmustine (150 mg/m2 every 6-8 weeks) and dacarbazine (660 mg/m2) and cisplatin (75 mg/m2) every 3 to 4 weeks in an infusion center plus tamoxifen (20 mg/day)." | 5.08 | Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. ( Byrd, DR; Fefer, A; Gold, PJ; Lindgren, CG; Markowitz, DR; Thompson, JA, 1997) |
| " This Phase II trial was designed to assess the efficacy of a strategy designed to modulate the resistance to carmustine (BCNU) mediated by AGAT using streptozocin (STZ) in patients with advanced refractory melanoma." | 5.08 | Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. ( Day, R; Donnelly, S; Gerson, SL; Kirkwood, JM; Liu, L; Smith, DC; Trump, DL, 1996) |
| "A phase II trial was conducted to determine the efficacy and toxicity of the addition of interferon-alpha 2b (IFN-alpha) to the chemotherapy combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV melanoma." | 5.08 | A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. ( Buzaid, AC; Poo, WJ; Schultz, MZ, 1997) |
| " Megestrol acetate may ameliorate cachexia, abrogate drug resistance, and increase survival time in melanoma." | 5.07 | Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin. ( Losada, R; Meelu, MA; Nathanson, L, 1994) |
| "A phase II study that alternates the sequence of chemotherapy (carmustine [BCNU], cisplatin [CDDP], and dacarbazine [DTIC]) and biologic therapy (interleukin-2 [IL-2] and interferon alfa-2 alpha [alpha IFN]) was performed to establish a safe and efficacious way to sequence these forms of treatment for metastatic melanoma." | 5.07 | Sequential chemoimmunotherapy in the treatment of metastatic melanoma. ( Mehta, N; Ramming, K; Richards, JM; Skosey, P, 1992) |
| "Laboratory data suggest a synergistic interaction between carmustine (BCNU) and tumour necrosis factor (TNF) in melanoma." | 5.07 | A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma. ( Gore, ME; Hanrahan, A; Jones, AL; Lorentzos, A; Millar, JL; Moore, J; O'Brien, ME; Viner, C, 1992) |
| "Thirty-three patients with malignant melanoma and regional lymph node metastases who underwent lymph node dissection were additionally given polychemotherapy with carmustine, hydroxycarbamide and dacarbazine immediately before surgery and up to five times postoperatively." | 5.06 | [Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma]. ( Aragon, V; Bröcker, EB; Bünte, H; Czarnetzki, BM; Krieg, V; Macher, E, 1986) |
| "In 1975, the Southwest Oncology Group initiated an adjuvant study in localized malignant melanoma testing the value of aggressive chemotherapy using carmustine, hydroxyurea, and dacarbazine versus a control arm." | 5.06 | Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. ( Balcerzak, SP; Costanzi, JH; Dixon, D; Fabian, CJ; Maloney, T; Neidhart, J; Neilan, B; O'Bryan, RM; Quagliana, J; Tranum, BL, 1987) |
| "We have attempted to review the data regarding the activity of tamoxifen (TAM) to clarify the role of this agent in the treatment of metastatic melanoma." | 4.79 | Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? ( McClay, EF; McClay, ME, 1994) |
| "Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma." | 3.72 | Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. ( Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY, 2003) |
| "In the present study, we have investigated the influence of telomerase inhibition in chemosensitivity of melanoma cells to temozolomide (TMZ), a methylating agent with promising antitumor activity against metastatic melanoma." | 3.72 | Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. ( Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M, 2003) |
| "Dacarbazine (DTIC) is the only single-agent approved by the Food and Drug Administration for treating metastatic melanoma." | 3.70 | Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. ( Cognetti, F; Sega, FM; Serrone, L; Zeuli, M, 2000) |
| "Intensive doses of carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support were given to four patients with advanced melanoma." | 3.68 | High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. ( Affronti, ML; Coniglio, D; Jones, RB; Peters, WP; Ross, M; Shpall, EJ, 1990) |
| "Exposure of cultured human melanoma cells from three different cell lines to Adriamycin and carmustine at non-cytotoxic (micromolar) concentrations results in a rapid, reversible depletion of cellular glutathione; maximal depletion is achieved within 1 h, and glutathione levels recover within 2-3 h." | 3.68 | Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine. ( Guenthner, TM; Jevtorić-Todorović, V; Jevtović-Todorović, V, 1991) |
| "Sixty-two patients with biopsy-proven, measurable disseminated malignant melanoma received either the combination IFN-alpha 2A with BCNU (30 patients) or the combination cimetidine with BCNU (32 patients) in parallel noncomparative Phase II trials." | 3.68 | Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma. ( Creagan, ET; Kardinal, CG; McCormack, GW; McHale, MS; Morton, RF; Schaid, DJ; Wiesenfeld, M, 1991) |
| "A prospective, nonrandomized trial was performed of the four-drug chemotherapy protocol consisting of dacarbazine, carmustine, cisplatin, and tamoxifen citrate given to high-risk patients for recurrence of melanoma after local regional treatment." | 3.68 | Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. ( Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE, 1992) |
| "Sodium cyanate injected IP at a dose level of 200 or 250 mg/kg caused a 90% or greater inhibition of the incorporation of [3H]thymidine into DNA of B16 melanoma transplanted SC in mice." | 3.67 | Effects of sodium cyanate in mice bearing B16 melanoma. ( Carpenter, L; Hill, GJ; Hill, HZ; Lea, MA; Luke, A; Martinson, CF; Velazquez, O, 1986) |
| "Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily." | 3.67 | Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987) |
| "High-dose chemotherapy with BCNU, melphalan, or both, followed by autologous bone marrow transplantation (ABMT) has been reported to produce response rates in excess of 60% in patients with advanced melanoma." | 3.67 | High-dose chemotherapy without autologous bone marrow transplantation in melanoma. ( Aisner, J; Tait, N; Tchekmedyian, NS; Van Echo, D, 1986) |
| "Sixteen patients with advanced (stage III) malignant melanoma were treated with escalating doses of intravenous BCNU and melphalan starting at 400 and 35 mg/m2, respectively, and escalating to 1,000 and 110 mg/m2, respectively, combined with autologous marrow transplantation." | 3.67 | Recovery of blood and bone marrow stem cells following intense chemotherapy and autologous bone marrow transplantation. ( Glode, LM; Morton, N; Mughal, TI; Robinson, WA; Thomas, MR, 1986) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 3.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Eight patients with advanced malignant melanoma were treated with high-dose melphalan (80-90 mg/m2) and BCNU (600-800 mg/m2)." | 3.67 | High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma. ( Havemann, K; Koeppler, H; Pflueger, KH; Seitz, R, 1989) |
| "The growth inhibitory effects, the reduction of [3H]-TdR incorporation and the perturbation of the cell cycle induced by the new agent mitozolomide on the M14 human melanoma cell line and on the SW626 human ovarian cancer cell line were compared to those produced by BCNU." | 3.67 | Mitozolomide activity on human cancer cells in vitro. ( D'Incalci, M; Erba, E; Landoni, F; Lorico, A; Mangioni, C; Morasca, L; Pepe, S; Ubezio, P, 1986) |
| "Thirteen patients with advanced (Stage III) malignant melanoma have been treated with high-dose chemotherapy (nitrogen mustard or a combination of BCNU and melphalan) combined with autologous, nonfrozen, bone marrow transplantation." | 3.66 | Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study. ( Dantas, ME; Glode, LM; Koeppler, H; Morton, N; Robinson, WA; Sutherland, J; Thomas, MR, 1982) |
| "The therapeutic usefulness of chlorpromazine (CPZ) and caffeine (CAF) in combination with selected nitrosoureas was investigated in mice bearing L1210 leukemia, Lewis lung carcinoma, and B16 melanoma." | 3.66 | Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. ( Dykes, DJ; Laster, WR; Rose, WC; Schabel, FM; Trader, MW, 1978) |
| "Sustained release of carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea, or BCNU) via an episcleral implanted silicone device was used to treat Greene hamster melanoma implanted in the anterior chamber of rabbit eyes." | 3.66 | Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy. ( Albert, DM; Liu, LH; Ni, C; Refojo, MF; Ueno, N, 1983) |
| "We investigated the effects of combinations of BCNU and misonidazole, and melphalan and misonidazole on growth delay in two human malignant melanoma xenograft lines grown in immune-deprived mice." | 3.66 | Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts. ( Clutterbuck, RD; McElwain, TJ; Millar, JL, 1982) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "A 43-year-old man with metastatic malignant melanoma was treated with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in combination with imidazole carboxamide and hydroxyurea." | 3.65 | Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea. ( Crittenden, D; Haut, A; Tranum, BL, 1977) |
| "One hundred twenty-one patients with disseminated malignant melanoma were treated with BCNU, vincristine, DTIC, and chlorpromazine (BVD)." | 3.65 | Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. ( Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK, 1977) |
| "We enrolled 25 patients with solitary brain metastases from lung (13 patients), melanoma (4 patients), breast (3 patients), and renal carcinoma (3 patients)." | 2.73 | Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. ( Brem, S; Carey, LA; Cush, S; Ewend, MG; Gilbert, M; Goodkin, R; Penar, PL; Varia, M, 2007) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults and the liver is the most common site for systemic metastases." | 2.71 | Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. ( Berd, D; Mastrangelo, MJ; Patel, K; Sato, T; Shields, CL; Shields, JA; Sullivan, K, 2005) |
| "Metastatic melanoma has a grim prognosis." | 2.68 | Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. ( Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T, 1995) |
| "Melanoma is rare in Singapore with an age-standardised rate (ASR) of 0." | 2.68 | Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. ( Ang, PT; Tan, EH, 1996) |
| " These data suggest that currently used filgrastim dosing strategies following autologous bone marrow transplantation may be suboptimal." | 2.68 | Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation. ( Peters, WP; Petros, WP; Rabinowitz, J; Stuart, A, 1997) |
| "173 patients with regional lymphatic metastases (n = 139) or distant disease (n = 34) were prospectively randomised, following resection of all clinically detectable tumour, to observation (n = 88) or adjuvant chemotherapy (n = 85)." | 2.67 | Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. ( Blumenson, L; Karakousis, C, 1993) |
| "The incidence of brain metastases was neither lowered nor delayed by the presence of BCNU in regimens A and C." | 2.64 | Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. ( Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U, 1976) |
| "It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men." | 2.64 | Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976) |
| "Cerebral metastases were the sole or major cause of death in 8/9 patients who relapsed following control with DTIC for nine months or longer, and one patient developed a carcinoma of the breast following therapy with DTIC and BCNU." | 2.64 | Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). ( Berris, R; Hill, GJ; Parkin, P; Philpott, GW; Ruess, R, 1974) |
| "In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective." | 2.37 | High dose chemotherapy in solid tumours in adults. ( Peters, W; Souhami, R, 1986) |
| "The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment." | 1.29 | Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. ( Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M, 1994) |
| "Metastatic melanoma is difficult to treat because of low response rates to most chemotherapy regimens and short remission durations." | 1.29 | The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. ( Crowell, EB; Higa, GM, 1993) |
| "Melphalan was administered as a bolus oral dose, using 2-mg tablets." | 1.28 | Pharmacokinetics of very high-dose oral melphalan in cancer patients. ( Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE, 1990) |
| "Fotemustine (S 10036) is a new anti-tumor nitrosourea characterized by a phosphonoalanine carrier group coupled to the nitrosourea moiety, which potentially increases the cellular penetration of the drug." | 1.28 | In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. ( Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G, 1990) |
| "Of 16 evaluable patients with breast cancer, 15 responded (six complete responses)." | 1.27 | High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. ( Andersen, J; Antman, K; Eder, JP; Elias, A; Finberg, R; Henner, WD; Peters, WP; Schryber, S; Shea, T; Wilmore, D, 1987) |
| "Both patients developed pulmonary fibrosis, which was visible in postmortem examination." | 1.26 | Pulmonary fibrosis following low-dose 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) therapy. ( Melato, M; Tuveri, G, 1980) |
| "Human malignant melanoma was transplanted to the cheek pouch of immunosuppressed (corticosteroid-treated) hamsters." | 1.26 | Chemotherapy against human melanoma in the hamster cheek pouch. ( Dufour, FD; Mah, SG; Morton, DL; Okada, GT, 1980) |
| "Greene melanoma was transplanted into the anterior chamber of rabbit eyes." | 1.26 | Experimental combined systemic and local chemotherapy for intraocular malignancy. ( Albert, DM; Liu, HS; Refojo, MF, 1980) |
| "Nine instances of hepatic metastases were unaffected by therapy but 68% of the skin and nodal patients responded." | 1.26 | Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine. ( Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ, 1977) |
| "Thirty-one patients with metastatic brain tumors (MBT) from lung cancer and ten patients with MBT from melanoma received BCNU, 100 mg/m2, every four weeks by intracarotid and/or vertebral artery infusion into each involved site." | 1.26 | Phase II study--intra-arterial BCNU therapy for metastatic brain tumors. ( Avellanosa, AM; Caracandas, J; Ghoorah, J; Jennings, E; Karakousis, C; Madajewicz, S; Park, HC; Takita, H; Vincent, R; West, CR, 1981) |
| "In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug." | 1.26 | Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study. ( Burk, MW; Campbell, MA; Giuliano, AE; Kaiser, LR; Kern, DH; Mann, BD; Morton, DL, 1982) |
| "All patients had extensive metastases in soft tissues, intestines and, some of them, in bone." | 1.26 | [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)]. ( Kleeberg, UR; Schreml, W, 1976) |
| "Survival curves are presented for the treatment of B16 melanomas with a range of single doses of cyclophosphamide (CY), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), or 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl)-1-nitro-sourea (MeCCNU)." | 1.25 | The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. ( Hill, RP; Stanley, JA, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 100 (54.05) | 18.7374 |
| 1990's | 56 (30.27) | 18.2507 |
| 2000's | 26 (14.05) | 29.6817 |
| 2010's | 3 (1.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gonsalves, CF | 1 |
| Eschelman, DJ | 1 |
| Thornburg, B | 1 |
| Frangos, A | 1 |
| Sato, T | 2 |
| Bei, D | 1 |
| Meng, J | 1 |
| Youan, BB | 1 |
| Lupov, IP | 1 |
| Voiles, L | 1 |
| Han, L | 1 |
| Schwartz, A | 1 |
| De La Rosa, M | 1 |
| Oza, K | 1 |
| Pelloso, D | 1 |
| Sahu, RP | 1 |
| Travers, JB | 1 |
| Robertson, MJ | 1 |
| Chang, HC | 1 |
| Stein, ME | 2 |
| Bernstein, Z | 2 |
| Tsalic, M | 1 |
| Drumea, K | 2 |
| Steiner, M | 2 |
| Sklar, Z | 1 |
| Haim, N | 2 |
| Debiton, E | 1 |
| Glasser, AL | 1 |
| Marchenay, C | 1 |
| Rolhion, C | 1 |
| Maurizis, JC | 1 |
| Madelmont, JC | 1 |
| Li, Y | 1 |
| McClay, EF | 5 |
| Tentori, L | 1 |
| Portarena, I | 1 |
| Barbarino, M | 1 |
| Balduzzi, A | 1 |
| Levati, L | 1 |
| Vergati, M | 1 |
| Biroccio, A | 1 |
| Gold, B | 1 |
| Lombardi, ML | 1 |
| Graziani, G | 1 |
| Pepponi, R | 1 |
| Marra, G | 1 |
| Fuggetta, MP | 1 |
| Falcinelli, S | 1 |
| Pagani, E | 1 |
| Bonmassar, E | 1 |
| Jiricny, J | 1 |
| D'Atri, S | 1 |
| Wojtukiewicz, MZ | 1 |
| Kozlowski, L | 1 |
| Ostrowska, K | 1 |
| Dmitruk, A | 1 |
| Zacharski, LR | 1 |
| Wolchok, JD | 1 |
| Williams, L | 1 |
| Pinto, JT | 1 |
| Fleisher, M | 1 |
| Krown, SE | 1 |
| Hwu, WJ | 1 |
| Livingston, PO | 1 |
| Chang, C | 1 |
| Chapman, PB | 2 |
| Ridolfi, R | 3 |
| Tanganelli, L | 1 |
| Scelzi, E | 1 |
| Manente, P | 1 |
| Palmeri, S | 1 |
| Ravaioli, A | 1 |
| Fiammenghi, L | 1 |
| Romanini, A | 3 |
| Chiarion-Sileni, V | 2 |
| Del Bianco, P | 1 |
| De Salvo, GL | 1 |
| Lo Re, G | 2 |
| Labianca, R | 2 |
| Nortilli, R | 2 |
| Corgna, E | 1 |
| Dalla Palma, M | 1 |
| Lo Presti, G | 1 |
| Akimov, MA | 1 |
| Gel'fond, ML | 1 |
| Gershanovich, ML | 1 |
| Barchuk, AS | 1 |
| Passagne, I | 1 |
| Evrard, A | 1 |
| Winum, JY | 1 |
| Depeille, P | 1 |
| Cuq, P | 1 |
| Montero, JL | 1 |
| Cupissol, D | 1 |
| Vian, L | 1 |
| Lens, MB | 1 |
| Eisen, TG | 1 |
| Feun, L | 1 |
| Marini, A | 1 |
| Moffat, F | 2 |
| Savaraj, N | 3 |
| Hurley, J | 2 |
| Mazumder, A | 1 |
| Patel, K | 1 |
| Sullivan, K | 1 |
| Berd, D | 6 |
| Mastrangelo, MJ | 7 |
| Shields, CL | 1 |
| Shields, JA | 1 |
| Gajewski, TF | 1 |
| Sosman, J | 1 |
| Gerson, SL | 2 |
| Liu, L | 2 |
| Dolan, E | 1 |
| Lin, S | 1 |
| Vokes, EE | 1 |
| Ewend, MG | 1 |
| Brem, S | 1 |
| Gilbert, M | 1 |
| Goodkin, R | 1 |
| Penar, PL | 1 |
| Varia, M | 1 |
| Cush, S | 1 |
| Carey, LA | 1 |
| Li, RH | 1 |
| Tam, WH | 1 |
| Ng, PC | 1 |
| Mok, TS | 1 |
| Tam, B | 1 |
| Lau, TK | 1 |
| Seigler, HF | 2 |
| Lucas, VS | 1 |
| Pickett, NJ | 1 |
| Huang, AT | 1 |
| Mann, BD | 1 |
| Kern, DH | 1 |
| Giuliano, AE | 1 |
| Burk, MW | 1 |
| Campbell, MA | 1 |
| Kaiser, LR | 1 |
| Morton, DL | 2 |
| Cohen, SM | 3 |
| Ohnuma, T | 1 |
| Cheung, T | 1 |
| Holland, JF | 2 |
| Osieka, R | 1 |
| Glatte, P | 1 |
| Pannenbäcker, R | 1 |
| Schmidt, CG | 1 |
| Madajewicz, S | 1 |
| West, CR | 1 |
| Park, HC | 1 |
| Ghoorah, J | 1 |
| Avellanosa, AM | 1 |
| Takita, H | 1 |
| Karakousis, C | 2 |
| Vincent, R | 1 |
| Caracandas, J | 1 |
| Jennings, E | 1 |
| Phillips, GL | 1 |
| Fay, JW | 1 |
| Herzig, GP | 1 |
| Herzig, RH | 1 |
| Weiner, RS | 1 |
| Wolff, SN | 1 |
| Lazarus, HM | 1 |
| Karanes, C | 1 |
| Ross, WE | 1 |
| Kramer, BS | 1 |
| Costanzi, JJ | 3 |
| Fletcher, WS | 3 |
| Balcerzak, SP | 2 |
| Taylor, S | 1 |
| Eyre, HJ | 1 |
| O'Bryan, RM | 2 |
| Al-Sarraf, M | 1 |
| Frank, J | 1 |
| Hill, GJ | 5 |
| Krementz, ET | 2 |
| Hill, HZ | 2 |
| Fingert, HJ | 1 |
| Hochberg, FH | 1 |
| Stein, BS | 1 |
| Kendall, AR | 1 |
| Del Prete, SA | 1 |
| Maurer, LH | 2 |
| O'Donnell, J | 2 |
| Forcier, RJ | 2 |
| LeMarbre, P | 1 |
| Klemm-Mayer, H | 1 |
| Rasokat, H | 1 |
| Wagner, G | 1 |
| Mughal, TI | 2 |
| Robinson, WA | 3 |
| Thomas, MR | 3 |
| Glode, LM | 3 |
| Dantas, ME | 1 |
| Koeppler, H | 2 |
| Morton, N | 2 |
| Sutherland, J | 1 |
| Weiss, RB | 1 |
| Issell, BF | 1 |
| Murray, JL | 2 |
| Ni, C | 2 |
| Liu, LH | 2 |
| Refojo, MF | 2 |
| Ueno, N | 1 |
| Albert, DM | 2 |
| Dumont, P | 1 |
| Atassi, G | 1 |
| Tagnon, HJ | 1 |
| Clutterbuck, RD | 1 |
| Millar, JL | 2 |
| McElwain, TJ | 1 |
| Robertson, DM | 1 |
| Wilkinson, CP | 1 |
| Gordy, DD | 1 |
| Nicolson, GL | 1 |
| Lotan, R | 1 |
| Rios, A | 1 |
| Melato, M | 1 |
| Tuveri, G | 1 |
| Liu, HS | 1 |
| Dufour, FD | 1 |
| Okada, GT | 1 |
| Mah, SG | 1 |
| Snyder, RD | 1 |
| Hortobagyi, GN | 1 |
| Bodey, GP | 3 |
| Gutterman, JU | 2 |
| Hersh, EM | 4 |
| Feun, LG | 2 |
| Robinson, D | 1 |
| Liebmann, A | 1 |
| Raub, WA | 1 |
| Richman, SP | 1 |
| Schadendorf, D | 1 |
| Worm, M | 1 |
| Algermissen, B | 1 |
| Kohlmus, CM | 1 |
| Czarnetzki, BM | 2 |
| Atzpodien, J | 4 |
| Lopez Hänninen, E | 1 |
| Kirchner, H | 2 |
| Franzke, A | 2 |
| Körfer, A | 1 |
| Volkenandt, M | 1 |
| Duensing, S | 1 |
| Schomburg, A | 1 |
| Chaitchik, S | 1 |
| Poliwoda, H | 2 |
| Rabinowitz, J | 2 |
| Petros, WP | 2 |
| Stuart, AR | 1 |
| Peters, WP | 7 |
| Muhonen, T | 1 |
| Pyrhönen, S | 1 |
| Laasonen, A | 1 |
| Wasenius, VM | 1 |
| Asko-Seljavaara, S | 1 |
| Franssila, K | 1 |
| Kangas, L | 1 |
| McClay, ME | 1 |
| Kitchell, BE | 1 |
| Brown, DM | 1 |
| Luck, EE | 1 |
| Woods, LL | 1 |
| Orenberg, EK | 1 |
| Bloch, DA | 1 |
| Becker, JC | 1 |
| Winkler, B | 1 |
| Klingert, S | 1 |
| Bröcker, EB | 3 |
| Blumenson, L | 1 |
| Nathanson, L | 2 |
| Meelu, MA | 1 |
| Losada, R | 1 |
| Crowell, EB | 1 |
| Higa, GM | 1 |
| Meisenberg, BR | 1 |
| Ross, M | 2 |
| Vredenburgh, JJ | 1 |
| Jones, R | 1 |
| Shpall, EJ | 3 |
| Coniglio, DM | 1 |
| Wu, K | 1 |
| Fierro, MT | 1 |
| Bertero, M | 1 |
| Novelli, M | 1 |
| Appino, A | 1 |
| Doveil, GC | 1 |
| Colonna, S | 1 |
| Bernengo, MG | 1 |
| Lattanzi, SC | 1 |
| Tosteson, T | 1 |
| Chertoff, J | 1 |
| LeMarbre, PJ | 1 |
| Mott, L | 1 |
| DelPrete, SA | 1 |
| Ernstoff, MS | 2 |
| Rusthoven, JJ | 1 |
| Quirt, IC | 1 |
| Iscoe, NA | 1 |
| McCulloch, PB | 1 |
| James, KW | 1 |
| Lohmann, RC | 1 |
| Jensen, J | 1 |
| Burdette-Radoux, S | 1 |
| Bodurtha, AJ | 2 |
| Silver, HK | 1 |
| Verma, S | 1 |
| Armitage, GR | 1 |
| Zee, B | 1 |
| Bennett, K | 1 |
| Kirchner, HH | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Thompson, JA | 2 |
| Gold, PJ | 2 |
| Fefer, A | 2 |
| Schultz, MZ | 1 |
| Buzaid, AC | 4 |
| Poo, WJ | 1 |
| Benathan, M | 1 |
| Fruehauf, JP | 2 |
| Zonis, S | 2 |
| al-Bassam, M | 2 |
| Kyshtoobayeva, A | 2 |
| Dasgupta, C | 2 |
| Milovanovic, T | 2 |
| Parker, RJ | 2 |
| Markowitz, DR | 1 |
| Byrd, DR | 1 |
| Lindgren, CG | 1 |
| Stark, JJ | 1 |
| Dillman, RO | 2 |
| Schulof, R | 2 |
| Wiemann, MC | 2 |
| Barth, NM | 1 |
| Honeycutt, PJ | 1 |
| Soori, G | 2 |
| Johnston, SR | 1 |
| Constenla, DO | 1 |
| Moore, J | 2 |
| Atkinson, H | 1 |
| A'Hern, RP | 1 |
| Dadian, G | 1 |
| Riches, PG | 1 |
| Gore, ME | 2 |
| Hoffmann, R | 1 |
| Müller, I | 2 |
| Neuber, K | 2 |
| Lassmann, S | 1 |
| Buer, J | 1 |
| Probst, M | 1 |
| Oevermann, K | 1 |
| Ganser, A | 1 |
| Stuart, A | 1 |
| Smith, DC | 1 |
| Donnelly, S | 1 |
| Day, R | 1 |
| Trump, DL | 1 |
| Kirkwood, JM | 2 |
| Zalik, M | 1 |
| Shklar, Z | 1 |
| Richards, JM | 4 |
| Gale, D | 1 |
| Mehta, N | 2 |
| Lestingi, T | 1 |
| Creagan, ET | 5 |
| Suman, VJ | 1 |
| Dalton, RJ | 1 |
| Pitot, HC | 1 |
| Long, HJ | 2 |
| Veeder, MH | 2 |
| Vukov, AM | 1 |
| Rowland, KM | 1 |
| Krook, JE | 1 |
| Michalak, JC | 1 |
| Einhorn, LH | 2 |
| Meyers, ML | 1 |
| Saxman, S | 1 |
| Destro, AN | 1 |
| Panageas, KS | 1 |
| Begg, CB | 1 |
| Agarwala, SS | 1 |
| Schuchter, LM | 1 |
| Houghton, AN | 1 |
| Middleton, MR | 1 |
| Lorigan, P | 1 |
| Owen, J | 1 |
| Ashcroft, L | 1 |
| Lee, SM | 1 |
| Harper, P | 1 |
| Thatcher, N | 1 |
| Propper, DJ | 1 |
| Braybrooke, JP | 1 |
| Levitt, NC | 1 |
| O'Byrne, K | 1 |
| Christodoulos, K | 1 |
| Han, C | 1 |
| Talbot, DC | 1 |
| Ganesan, TS | 1 |
| Harris, AL | 1 |
| Serrone, L | 1 |
| Zeuli, M | 1 |
| Sega, FM | 1 |
| Cognetti, F | 1 |
| Schachter, J | 1 |
| Rakowsky, E | 1 |
| Sulkes, A | 1 |
| Adler, A | 1 |
| Keilholz, U | 1 |
| Suciu, S | 1 |
| Eggermont, AM | 1 |
| Protheroe, AS | 1 |
| Pickard, C | 1 |
| Johnson, PW | 1 |
| Craddock, T | 1 |
| Shefta, J | 1 |
| Short, K | 1 |
| Lancaster, F | 1 |
| Selby, PJ | 1 |
| Henwood, J | 1 |
| Boylston, AW | 1 |
| Dobbs, TW | 1 |
| Ruben, RH | 1 |
| DePriest, CB | 1 |
| Church, C | 1 |
| Jelić, S | 1 |
| Babovic, N | 1 |
| Kovcin, V | 1 |
| Milicevic, N | 1 |
| Milanovic, N | 1 |
| Popov, I | 1 |
| Radosavljevic, D | 1 |
| Kamanabrou, D | 1 |
| Fluck, M | 1 |
| Neumann, C | 1 |
| Rünger, TM | 1 |
| Schuler, G | 1 |
| von den Driesch, P | 1 |
| Paul, E | 1 |
| Patzelt, T | 1 |
| Reitz, M | 1 |
| Guida, M | 1 |
| Freschi, A | 1 |
| Brugnara, S | 1 |
| Vitali, P | 1 |
| Nanni, O | 1 |
| Cohen, SC | 1 |
| Gabelnick, HL | 1 |
| Johnson, RK | 1 |
| Goldin, A | 1 |
| Mabel, JA | 1 |
| Merker, PC | 1 |
| Sturgeon, ML | 1 |
| Wodinsky, I | 1 |
| Geran, RI | 1 |
| Bellet, RE | 3 |
| Danna, V | 1 |
| Wilson, CB | 2 |
| Gutin, P | 1 |
| Boldrey, EB | 2 |
| Drafts, D | 1 |
| Levin, VA | 1 |
| Enot, KJ | 2 |
| Paterson, AH | 1 |
| McPherson, TA | 2 |
| Willans, DJ | 1 |
| Spitzer, G | 1 |
| Dicke, KA | 1 |
| Verma, DS | 1 |
| Zander, A | 1 |
| McCredie, KB | 1 |
| Hemsworth, GR | 1 |
| Wolff, JS | 1 |
| Kraska, AR | 1 |
| Jensen, KE | 1 |
| Rose, WC | 1 |
| Trader, MW | 1 |
| Dykes, DJ | 2 |
| Laster, WR | 1 |
| Schabel, FM | 3 |
| Comis, RL | 1 |
| Johnson, RO | 2 |
| Metter, G | 2 |
| Wilson, W | 1 |
| Hill, G | 1 |
| Krementz, E | 1 |
| Carbone, PP | 1 |
| Costello, W | 1 |
| Ahmann, DL | 2 |
| Hunter, JA | 1 |
| Bellett, RE | 1 |
| Laucius, JF | 1 |
| Wilson, WL | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Golomb, FM | 2 |
| Cruz, AB | 1 |
| McKelvey, EM | 2 |
| Luce, JK | 5 |
| Talley, RW | 2 |
| Hewlett, JS | 1 |
| Moon, TE | 2 |
| Greenspan, EM | 2 |
| Ratner, LH | 1 |
| Weiner, MJ | 2 |
| Vaitkevicius, VK | 2 |
| Lane, M | 1 |
| Aranha, GV | 1 |
| Grage, TB | 2 |
| Crittenden, D | 1 |
| Tranum, BL | 2 |
| Haut, A | 1 |
| Carter, RD | 1 |
| Metter, GE | 1 |
| Minton, JP | 2 |
| Sparks, FC | 1 |
| Beretta, G | 1 |
| Bonadonna, G | 1 |
| Cascinelli, N | 1 |
| Morabito, A | 1 |
| Veronesi, U | 2 |
| Brufman, G | 1 |
| Biran, S | 1 |
| Ratzkowski, E | 1 |
| Carmo-Pereira, J | 1 |
| Oliveira Costa, F | 1 |
| Pimentel, P | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 2 |
| Moon, JH | 1 |
| Gailani, S | 1 |
| Cooper, MR | 1 |
| Hayes, DM | 1 |
| Rege, VB | 1 |
| Blom, J | 2 |
| Falkson, G | 2 |
| Maurice, P | 1 |
| Brunner, K | 1 |
| Glidewell, O | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 1 |
| Hill, RP | 1 |
| Stanley, JA | 1 |
| Van Dyk, JJ | 1 |
| Griswold, DP | 1 |
| Kleeberg, UR | 1 |
| Schreml, W | 1 |
| Jevtović-Todorović, V | 2 |
| Guenthner, TM | 2 |
| Jones, AL | 1 |
| O'Brien, ME | 1 |
| Lorentzos, A | 1 |
| Viner, C | 1 |
| Hanrahan, A | 1 |
| Murren, J | 1 |
| Ramming, K | 2 |
| Skosey, P | 1 |
| Saba, HI | 2 |
| Cruse, CW | 2 |
| Wells, KE | 2 |
| Klein, CJ | 2 |
| Reintgen, DS | 2 |
| Kanj, SS | 1 |
| Sharara, AI | 1 |
| Jones, RB | 2 |
| Lee, YY | 1 |
| Plager, C | 1 |
| Papadopoulos, N | 1 |
| Charnsangavej, C | 1 |
| Benjamin, RS | 1 |
| Wallace, S | 1 |
| Glover, DJ | 1 |
| Basile, M | 1 |
| Moskowitz, B | 1 |
| Harris, J | 1 |
| Blumberg, N | 1 |
| Bennett, JM | 1 |
| Gilewski, TA | 1 |
| Mitchel, B | 1 |
| Doane, LL | 1 |
| Vogelzang, NJ | 1 |
| Boaziz, C | 1 |
| Breau, JL | 1 |
| Morere, JF | 1 |
| Israël, L | 1 |
| Comella, G | 1 |
| Daponte, A | 1 |
| Comella, P | 1 |
| Casaretti, R | 1 |
| Iervolino, V | 1 |
| Santillo, G | 1 |
| Zarrilli, D | 1 |
| Morton, RF | 2 |
| Schaid, DJ | 2 |
| Kardinal, CG | 1 |
| McCormack, GW | 1 |
| McHale, MS | 1 |
| Wiesenfeld, M | 1 |
| Jevtorić-Todorović, V | 1 |
| Frytak, S | 1 |
| Coniglio, D | 1 |
| Affronti, ML | 1 |
| Boros, L | 1 |
| Peng, YM | 1 |
| Alberts, DS | 1 |
| Asbury, RF | 1 |
| Goodman, TL | 1 |
| Penn, TE | 1 |
| Hickox, DE | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Etienne, MC | 1 |
| Gioanni, J | 1 |
| Frenay, M | 1 |
| Deloffre, P | 1 |
| Bizzari, JP | 1 |
| Milano, G | 1 |
| Panella, TJ | 1 |
| Peters, W | 2 |
| White, JG | 1 |
| Hannun, YA | 1 |
| Greenberg, CS | 1 |
| Pflueger, KH | 1 |
| Seitz, R | 1 |
| Havemann, K | 1 |
| Wang, YY | 1 |
| Teicher, BA | 1 |
| Shea, TC | 2 |
| Holden, SA | 1 |
| Rosbe, KW | 1 |
| al-Achi, A | 1 |
| Henner, WD | 3 |
| Sprandio, JD | 1 |
| Souhami, R | 1 |
| Antman, KH | 1 |
| Eder, JP | 2 |
| Elias, A | 2 |
| Schryber, S | 2 |
| Schoenfeld, DA | 1 |
| Schnipper, LE | 1 |
| Frei, E | 2 |
| Karakousis, CP | 1 |
| Emrich, LJ | 1 |
| Tchekmedyian, NS | 1 |
| Tait, N | 1 |
| Van Echo, D | 1 |
| Aisner, J | 1 |
| Appelbaum, FR | 1 |
| Antman, K | 1 |
| Shea, T | 1 |
| Andersen, J | 1 |
| Finberg, R | 1 |
| Wilmore, D | 1 |
| Elson, DL | 1 |
| Laurie, JA | 1 |
| Nelimark, RA | 1 |
| Chang, MN | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| Dixon, D | 1 |
| Quagliana, J | 1 |
| Neidhart, J | 1 |
| Costanzi, JH | 1 |
| Fabian, CJ | 1 |
| Neilan, B | 1 |
| Maloney, T | 1 |
| Grimmond, HE | 1 |
| Zirvi, KA | 1 |
| Kiryi, KA | 1 |
| Aragon, V | 1 |
| Krieg, V | 1 |
| Bünte, H | 1 |
| Macher, E | 1 |
| Schutt, AJ | 1 |
| Green, SJ | 1 |
| Lea, MA | 1 |
| Luke, A | 1 |
| Velazquez, O | 1 |
| Carpenter, L | 1 |
| Martinson, CF | 1 |
| Erba, E | 1 |
| Pepe, S | 1 |
| Ubezio, P | 1 |
| Lorico, A | 1 |
| Morasca, L | 1 |
| Mangioni, C | 1 |
| Landoni, F | 1 |
| D'Incalci, M | 1 |
| Sulis, E | 1 |
| Floris, C | 1 |
| Chessa, A | 1 |
| Desogus, A | 1 |
| Muggiano, A | 1 |
| Tedde, A | 1 |
| Turno, R | 1 |
| Clamon, G | 1 |
| Sinkey, C | 1 |
| Jochimsen, P | 1 |
| Berranco, SC | 1 |
| Drewinko, B | 1 |
| Humphrey, RM | 1 |
| Wagenknecht, L | 1 |
| Sigel, MM | 1 |
| Lichter, W | 1 |
| Lopez, DM | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Fewer, D | 1 |
| Powell, MR | 1 |
| Schein, PS | 1 |
| O'Connell, MJ | 1 |
| Hubbard, S | 1 |
| Magrath, IT | 1 |
| Bergevin, P | 1 |
| Wiernik, PH | 1 |
| Ziegler, JL | 1 |
| DeVita, VT | 1 |
| Kabakow, B | 1 |
| Primack, A | 1 |
| Dhru, D | 1 |
| Kiryabwire, JW | 1 |
| Vogel, CL | 1 |
| Ruess, R | 1 |
| Berris, R | 1 |
| Philpott, GW | 1 |
| Parkin, P | 1 |
| Costanza, ME | 1 |
| Lenhard, R | 1 |
| Wolter, J | 1 |
| Colsky, J | 1 |
| Oberfield, RA | 1 |
| Schilling, A | 1 |
| Garin, AM | 1 |
| Lichinitser, MR | 1 |
| Moroz, LV | 1 |
| Bajetta, E | 1 |
| Burgess, MA | 2 |
| Vallejos, C | 1 |
| Gutterman, J | 1 |
| Mavligit, G | 2 |
| Freireich, EJ | 2 |
| Gottlieb, JA | 2 |
| McBride, CE | 1 |
| Einhorn, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma[NCT00226473] | Phase 4 | 200 participants | Interventional | 2001-09-30 | Recruiting | ||
| Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma[NCT00683670] | Phase 1 | 17 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases[NCT01703507] | Phase 1 | 17 participants (Actual) | Interventional | 2012-11-09 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(MTD) when combined with WBRT or SRS, defined as the last dose studied or the previous dose, based on clinical judgment of the degree of toxicity seen at the last dose (NCT01703507)
Timeframe: 30 days following the completion of radiation therapy
| Intervention | mg/kg (Number) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 3 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 10 |
(NCT01703507)
Timeframe: 4 weeks following the last dose of ipilimumab
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 1 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 4 |
(NCT01703507)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 8 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 10.5 |
PFS rate based on Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC) criteria based on the brain MRI and systematic assessment by the treating physician (NCT01703507)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 3 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 3 |
(NCT01703507)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 8.2 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 1.9 |
Extracranial disease is assessed through repeated computed tomography of the chest, abdomen, and pelvis. The purpose of this scan is to determine if there is any evidence of disease outside of the brain. (NCT01703507)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Ipilimumab and Whole Brain Radiation Therapy) | 0 |
| Arm B (Ipilimumab and Stereotactic Radiosurgery) | 5 |
16 reviews available for carmustine and Malignant Melanoma
| Article | Year |
|---|---|
Engineering nanomedicines for improved melanoma therapy: progress and promises.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; | 2010 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmu | 2002 |
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as | 2003 |
Malignant melanoma of the genitourinary tract.
Topics: Adrenal Gland Neoplasms; Adult; Aged; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazin | 1984 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Synergism; | 1994 |
The Dartmouth Regimen: gone or going strong?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Dac | 1998 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; | 1976 |
Nitrosoureas: a review of experimental antitumor activity.
Topics: Animals; Carmustine; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, | 1976 |
Cutaneous malignant melanoma.
Topics: Adult; Aged; Biopsy; Carmustine; Cyclophosphamide; Dactinomycin; Female; Humans; Hydroxyurea; Male; | 1976 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interl | 1991 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
Chemotherapy of malignant melanoma.
Topics: Alkylating Agents; Amides; Animals; Antigen-Antibody Reactions; Antimetabolites; Antineoplastic Agen | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
66 trials available for carmustine and Malignant Melanoma
| Article | Year |
|---|---|
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 2002 |
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; C | 2003 |
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Carmusti | 2003 |
Chemotherapy and bio-chemotherapy in patients with advanced melanoma: combination therapy with a nitrosourea.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality | 2003 |
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 2003 |
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cis | 2003 |
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 2005 |
Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carmustine; Chemoembolization, Th | 2005 |
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2005 |
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carmustine; Combi | 2007 |
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; D | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1995 |
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 1995 |
Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmusti | 1993 |
Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexi | 1994 |
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisp | 1993 |
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cis | 1993 |
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmust | 1995 |
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Dis | 1996 |
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Com | 1996 |
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 1996 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 1997 |
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Comb | 1997 |
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1997 |
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Da | 1998 |
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Daca | 1998 |
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1998 |
Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1997 |
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Glutat | 1996 |
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; | 1999 |
Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1999 |
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 1999 |
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 2000 |
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2000 |
A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured | 1998 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 2000 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response | 2002 |
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 2002 |
Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Carmustine; Clinical Trials as Topic; Dacarbazine; Fem | 1978 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; | 1976 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combi | 1976 |
Nitrosoureas in the management of disseminated malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; | 1976 |
Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; | 1976 |
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; | 1976 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System | 1976 |
Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma.
Topics: Adult; Aged; Amides; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; Humans; I | 1975 |
A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Administra | 1992 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1992 |
Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Evaluation; Eflornithine; Fe | 1990 |
Adjuvant chemotherapy in high-risk malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Combined Modal | 1987 |
Phase II study of the combination of carmustine and 6-thioguanine in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1987 |
Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans | 1987 |
[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dacarbazine; | 1986 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Topics: Adenoma, Islet Cell; Blood Cells; Burkitt Lymphoma; Carcinoid Tumor; Carmustine; Clinical Trials as | 1974 |
Triple combination chemotherapy of disseminated melanoma.
Topics: Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Combinati | 1972 |
Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Female; Follow-Up Studies; Foot; Humans; Leukocyt | 1973 |
Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).
Topics: Adult; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cyclohe | 1974 |
105 other studies available for carmustine and Malignant Melanoma
| Article | Year |
|---|---|
Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carmustine; Chemoembolization, Th | 2015 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2011 |
Inhibition of O6-alkylguanine-DNA alkyltransferase by O6-benzyl-N2-acetylguanosine increases chloroethylnitrosourea-induced apoptosis in Mer+ human melanoma cells.
Topics: Animals; Apoptosis; Carmustine; Cattle; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme | 2002 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combina | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DN | 2003 |
Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Carmustine; DNA Damage; Enzyme Inhibitors; Enzyme-Linked Immunosor | 2003 |
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; H | 2007 |
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Drug Administration Schedule; Drug Evaluation; Drug Th | 1980 |
Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Hepatocellular; Carmustine; Cell Division; D | 1982 |
Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Female; Humans; | 1983 |
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans; | 1983 |
Phase II study--intra-arterial BCNU therapy for metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carmu | 1981 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1984 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female | 1984 |
Malignant melanoma and BCNU.
Topics: Aged; Carmustine; Heart Arrest; Humans; Male; Melanoma | 1984 |
Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; | 1982 |
Primary malignant melanoma metastatic to vitreous humor of the eye: treatment with BCNU.
Topics: Adult; Carmustine; Eye Neoplasms; Female; Humans; Melanoma; Vitreous Body | 1983 |
Histopathologic changes following carmustine treatment of uveal Greene melanoma in rabbits.
Topics: Animals; Carmustine; Female; Melanoma; Microscopy, Electron; Rabbits; Uveal Neoplasms | 1983 |
Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy.
Topics: Animals; Anterior Chamber; Carmustine; Cricetinae; Delayed-Action Preparations; Eye Neoplasms; Femal | 1983 |
Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Co | 1981 |
Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cell Line; Drug Synergism; Drug Therapy, Co | 1982 |
[Malignant melanoma].
Topics: Aminoimidazole Carboxamide; BCG Vaccine; Carmustine; Humans; Lymphatic Metastasis; Melanoma; Neck Di | 1981 |
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neo | 1981 |
Heterogeneous in vitro sensitivities of metastatic B16 melanoma sublines and clones to retinoic acid or BCNU.
Topics: Animals; Carmustine; Cell Line; Clone Cells; Drug Evaluation, Preclinical; Melanoma; Mice; Neoplasms | 1981 |
Pulmonary fibrosis following low-dose 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Topics: Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Melanoma; Middle Aged | 1980 |
Experimental combined systemic and local chemotherapy for intraocular malignancy.
Topics: Animals; Carmustine; Ciliary Body; Eye Neoplasms; Female; Injections; Injections, Intravenous; Iris; | 1980 |
Chemotherapy against human melanoma in the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cheek; Cricetinae; Cyclophosphamide; Da | 1980 |
Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin.
Topics: Adult; Aged; Bacterial Vaccines; Carmustine; Drug Administration Schedule; Female; Heparin; Humans; | 1981 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Rel | 1994 |
Combination chemotherapy of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma | 1995 |
Mouse subrenal capsule assay chemosensitivity and DNA flow cytometry parameters of human melanoma metastases.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarba | 1994 |
Intralesional implant for treatment of primary oral malignant melanoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Delayed-Action Prepa | 1994 |
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Topics: Adult; Aged; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antineoplastic Combined Chemothe | 1994 |
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Dru | 1993 |
Opposite regulation of tyrosinase and glutathione peroxidase by intracellular thiols in human melanoma cells.
Topics: Buthionine Sulfoximine; Carmustine; Cysteine; Cystine; Glutathione; Glutathione Peroxidase; Humans; | 1997 |
Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Buthionine Sul | 1997 |
Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buthionine Sulfoximine; Carmustine | 1998 |
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmus | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemo | 2000 |
Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Breast Neoplasms; Carci | 2000 |
Effects of antineoplastic agents on wound healing in mice.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Dactinomycin; Doxorubicin; | 1975 |
Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cisplatin; Dose-Response Relationship, Drug; | 1978 |
Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carmustine; Dacarbazine; Doxorubicin; Drug Evaluation, | 1979 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
Topics: Adult; Aged; Bone Marrow Transplantation; Carcinoma; Carmustine; Female; Freezing; Humans; Male; Mel | 1979 |
Delayed cutaneous hypersensitivity to oxazolone in mice with tumors.
Topics: Animals; Carmustine; Doxorubicin; Female; Hypersensitivity, Delayed; Leukemia, Experimental; Leukemi | 1978 |
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
Topics: Animals; Caffeine; Carmustine; Chlorpromazine; Drug Synergism; Drug Therapy, Combination; Female; Le | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
Topics: Carmustine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Ly | 1977 |
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasi | 1977 |
Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma.
Topics: Carmustine; Chlorpromazine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leu | 1977 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.
Topics: Adult; Carmustine; Drug Therapy, Combination; Humans; Hydroxyurea; Imidazoles; Male; Melanoma; Pulmo | 1977 |
[Results with new cytotoxic agents].
Topics: Carmustine; Dacarbazine; Gastrointestinal Neoplasms; Humans; Melanoma; Remission, Spontaneous; Triaz | 1976 |
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; | 1976 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Survival; Cyclophosphamide; Female; In Vitro Techni | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lu | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor.
Topics: Animals; Carmustine; Cell Line; Cells, Cultured; Melanoma; Mice; Neoplasm Transplantation; Neoplasms | 1976 |
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Mel | 1976 |
Depletion of a discrete nuclear glutathione pool by oxidative stress, but not by buthionine sulfoximine. Correlation with enhanced alkylating agent cytotoxicity to human melanoma cells in vitro.
Topics: Buthionine Sulfoximine; Carmustine; Cell Division; Cell Nucleus; Cytosol; Doxorubicin; Drug Synergis | 1992 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cis | 1992 |
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1992 |
Myocardial ischemia associated with high-dose carmustine infusion.
Topics: Adult; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1991 |
Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; | 1990 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1991 |
Malignant melanoma: primary presentation in bone marrow and lymph node.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; | 1992 |
Effective chemotherapy for melanoma after treatment with interleukin-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1992 |
Combination chemotherapy with vinblastine, BCNU and cisplatin in advanced malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Humans; Melanoma; Vinblastine | 1991 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cispla | 1991 |
Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cimetidine; Drug Evaluation | 1991 |
Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine.
Topics: Carmustine; Cell Cycle; Doxorubicin; Drug Interactions; Glutathione; Humans; Melanoma; Melphalan; Tu | 1991 |
High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Car | 1990 |
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biologi | 1990 |
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Ant | 1990 |
Platelets acquire a secretion defect after high-dose chemotherapy.
Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelet Disord | 1990 |
High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1989 |
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Topics: Alkylating Agents; Antineoplastic Agents; Blotting, Northern; Carmustine; Cell Line; Cell Survival; | 1989 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematolo | 1989 |
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisp | 1988 |
Recovery of blood and bone marrow stem cells following intense chemotherapy and autologous bone marrow transplantation.
Topics: Agranulocytosis; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Hematopoietic | 1986 |
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Di | 1986 |
Hammering away at solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1987 |
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1987 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1987 |
Biochemical analysis of the effects of 1,3-bis(2-chloroethyl)-1-nitrosourea on the growth of a human melanoma cell line.
Topics: Carmustine; Cell Line; Dose-Response Relationship, Drug; Humans; Melanoma; Molecular Weight; Neoplas | 1987 |
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dactinomycin; | 1986 |
Effects of sodium cyanate in mice bearing B16 melanoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmust | 1986 |
Mitozolomide activity on human cancer cells in vitro.
Topics: Aged; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Dose-Response Relationship, Drug; Fe | 1986 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Evaluation; Female; Hu | 1985 |
Differential response by human melanoma cells to 1,3-bis-(2-chloroethyl)-1-nitrosourea and bleomycin.
Topics: Bleomycin; Carmustine; Cell Division; Cells, Cultured; Humans; Melanoma | 1973 |
[Chemotherapy of malignant melanoma].
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Bleomycin; Carmustine; Cyclohexanes; Drug Therapy, | 1973 |
In vitro methods to complement in vivo approaches utilizing combinations of chemotherapy and immunotherapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Bleomycin; Carmustine; Cells, Cultured; Chickens | 1974 |
Editorial: Treatment of malignant melanoma.
Topics: Amides; Antibodies, Neoplasm; Antibody Formation; BCG Vaccine; Carmustine; Chlorine; Humans; Imidazo | 1974 |
Mumps virus and BCG vaccine in metastatic melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Carmustine; Female; Humans; Imm | 1973 |
Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea.
Topics: Amides; Antineoplastic Agents; Bone Marrow; Carmustine; Drug Synergism; Humans; Imidazoles; Lymph No | 1972 |
[Imidazole carboxamide in the treatment of disseminated melanoblastoma].
Topics: Amides; Carmustine; Humans; Hydroxyurea; Imidazoles; Lymphatic Metastasis; Melanoma; Neoplasm Metast | 1973 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Agents; Carmustine; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Ski | 1973 |
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Dexameth | 1974 |
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Topics: Adult; Aged; Amides; Antibody Formation; Antineoplastic Agents; BCG Vaccine; Carmustine; Drug Therap | 1974 |